These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32897830)

  • 1. Exploring Spatial-Temporal Changes in
    Kyriakopoulos CE; Heath EI; Ferrari A; Sperger JM; Singh A; Perlman SB; Roth AR; Perk TG; Modelska K; Porcari A; Duggan W; Lang JM; Jeraj R; Liu G
    J Clin Oncol; 2020 Nov; 38(31):3662-3671. PubMed ID: 32897830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative Assessment of Early [
    Harmon SA; Perk T; Lin C; Eickhoff J; Choyke PL; Dahut WL; Apolo AB; Humm JL; Larson SM; Morris MJ; Liu G; Jeraj R
    J Clin Oncol; 2017 Aug; 35(24):2829-2837. PubMed ID: 28654366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.
    Armstrong AJ; Al-Adhami M; Lin P; Parli T; Sugg J; Steinberg J; Tombal B; Sternberg CN; de Bono J; Scher HI; Beer TM
    JAMA Oncol; 2020 Feb; 6(2):217-225. PubMed ID: 31830211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide.
    Gandhy SU; Karzai FH; Bilusic M; McMahon S; Cordes LM; Marte J; Weisman AJ; Perk TG; Lindenberg L; Mena E; Turkbey B; Arlen PM; Dahut WL; Figg WD; Choyke P; Gulley JL; Madan RA
    Eur Urol Oncol; 2024 Aug; 7(4):735-741. PubMed ID: 37858437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
    BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
    Efstathiou E; Titus M; Wen S; Hoang A; Karlou M; Ashe R; Tu SM; Aparicio A; Troncoso P; Mohler J; Logothetis CJ
    Eur Urol; 2015 Jan; 67(1):53-60. PubMed ID: 24882673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of bone flare on
    Weisman AJ; Harmon SA; Perk TG; Eickhoff J; Choyke PL; Kurdziel KA; Dahut WL; Humm JL; Apolo AB; Larson SM; Morris MJ; Perlman SB; Liu G; Jeraj R
    Prostate Cancer Prostatic Dis; 2019 May; 22(2):324-330. PubMed ID: 30413807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer.
    Roth AR; Harmon SA; Perk TG; Eickhoff J; Choyke PL; Kurdziel KA; Dahut WL; Apolo AB; Morris MJ; Perlman SB; Liu G; Jeraj R
    Clin Genitourin Cancer; 2019 Aug; 17(4):306-314. PubMed ID: 31221545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
    De Giorgi U; Caroli P; Scarpi E; Conteduca V; Burgio SL; Menna C; Moretti A; Galassi R; Rossi L; Amadori D; Paganelli G; Matteucci F
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1276-83. PubMed ID: 25808631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
    Evans CP; Higano CS; Keane T; Andriole G; Saad F; Iversen P; Miller K; Kim CS; Kimura G; Armstrong AJ; Sternberg CN; Loriot Y; de Bono J; Noonberg SB; Mansbach H; Bhattacharya S; Perabo F; Beer TM; Tombal B
    Eur Urol; 2016 Oct; 70(4):675-683. PubMed ID: 27006332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
    Hussain M; Fizazi K; Saad F; Rathenborg P; Shore N; Ferreira U; Ivashchenko P; Demirhan E; Modelska K; Phung D; Krivoshik A; Sternberg CN
    N Engl J Med; 2018 Jun; 378(26):2465-2474. PubMed ID: 29949494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment.
    Attard G; Borre M; Gurney H; Loriot Y; Andresen-Daniil C; Kalleda R; Pham T; Taplin ME;
    J Clin Oncol; 2018 Sep; 36(25):2639-2646. PubMed ID: 30028657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial.
    Saad F; de Bono J; Shore N; Fizazi K; Loriot Y; Hirmand M; Franks B; Haas GP; Scher HI
    Eur Urol; 2015 Feb; 67(2):223-30. PubMed ID: 25171902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases.
    Donners R; Tunariu N; Tovey H; Hall E; Chua S; Cook G; Du Y; Blackledge MD; Parker CC; Koh DM
    Eur Radiol; 2024 Feb; 34(2):1146-1154. PubMed ID: 37615760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.
    Graff JN; Baciarello G; Armstrong AJ; Higano CS; Iversen P; Flaig TW; Forer D; Parli T; Phung D; Tombal B; Beer TM; Sternberg CN
    Ann Oncol; 2016 Feb; 27(2):286-94. PubMed ID: 26578735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
    Armstrong AJ; Lin P; Higano CS; Iversen P; Sternberg CN; Tombal B; Phung D; Parli T; Krivoshik A; Beer TM
    Eur Urol Oncol; 2019 Nov; 2(6):677-684. PubMed ID: 31274110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers.
    Maines F; Caffo O; Donner D; Sperduti I; Bria E; Veccia A; Chierichetti F; Tortora G; Galligioni E
    Future Oncol; 2016 Feb; 12(3):333-42. PubMed ID: 26768648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
    Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
    Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.